Startseite › Burkitt-Lymphom › Ohio › Cincinnati
Klinische Studien zu Burkitt-Lymphom in Cincinnati, OH
12 Studien zu Burkitt-Lymphom suchen Teilnehmer an Standorten in und um Cincinnati (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Teilnehmer gesuchtPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Teilnehmer gesuchtPhase 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi entfernt
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Teilnehmer gesuchtBeobachtungsstudie
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Teilnehmer gesuchtPhase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi entfernt
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Teilnehmer gesuchtPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Teilnehmer gesuchtPhase 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Teilnehmer gesuchtPhase 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Teilnehmer gesuchtPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Teilnehmer gesuchtPhase 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Teilnehmer gesuchtPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Teilnehmer gesuchtPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Teilnehmer gesuchtPhase 1
- University of Cincinnati, Cincinnati
Burkitt-Lymphom-Studien in anderen Städten
- Houston, TX21 Studien
- Milwaukee, WI16 Studien
- Philadelphia, PA16 Studien
- New York City, NY14 Studien
- Chicago, IL14 Studien
- Atlanta, GA12 Studien
- Seattle, WA11 Studien
- Boston, MA10 Studien
- Durham, NC10 Studien
- Aurora, CO10 Studien
- Los Angeles, CA10 Studien
- Kansas City, MO10 Studien
Weitere Studien in Cincinnati
- Nichtkleinzelliges Lungenkarzinom35 Studien
- Krebs (alle Arten)27 Studien
- Brustkrebs25 Studien
- Herzinsuffizienz24 Studien
- Kolorektales Karzinom21 Studien
- Akute myeloische Leukämie20 Studien
- Metastasierender Krebs20 Studien
- Eierstockkrebs19 Studien
- Lungenkrebs19 Studien
- Adipositas19 Studien
- Prostatakrebs18 Studien
- Multiples Myelom17 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.